These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
manuscript for SARS-CoV2 vaccine 20200512.pdf (1020.89 kB)

A Translatable Subunit Nanovaccine for COVID-19

submitted on 14.05.2020 and posted on 15.05.2020 by Lixin Liu, Zhijia Liu, Haolin Chen, Hong Liu, Qiang Gao, Feng Cong, Guangxia Gao, Yongming Chen
In order to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in the world, we formulate S1 subunit of the virus with two types of adjuvants, amphiphilic adjuvant monophosphoryl lipid A (MPLA) for Toll-like receptor 4 (TLR4) and CpG ODN for TLR9, into cationic multifunctional liposomes to produce a potent, safer, and translatable nanovaccine. The results show that the nanovaccine can efficiently elicit humoral immune response in mice. The sera from the vaccinated mice significantly inhibit SARS-CoV-2 to infect Vero cells. Moreover, relatively to the free S1 with traditional Alum adjuvant, the nanovaccine can elicit strong T cell immunity by activating both CD4+ and CD8+ cells, which may play critical roles in eliminating viral load in patients. Most importantly, the nanovaccine can elicit strong IgA antibody, providing potential mucosal protection to host. Altogether, this study offers a translatable design for a potent subunit SARS-CoV-2 nanovaccine.


the National Natural Science Foundation of China (51820105004)

the Guangdong Innovative and Entrepreneurial Research Team Program (2013S086)


Email Address of Submitting Author


Sun Yat-sen University



ORCID For Submitting Author


Declaration of Conflict of Interest

We declare no conflict of interest


Logo branding